. 2021 Oct 1;34(4):840–849. doi: 10.1111/den.14137

Table 6.

Overall and relapse‐free survival rates in the current and previous studies

	Study design	Setting	n	3‐year OS	5‐year OS	3‐year RFS
Current study	Prospective cohort study	BTS	208	77.4%	67.4%	65.6%
Amelung et al. 2019 ^† ^, ¹⁷	Retrospective ITT analysis	ES	444	68.3%
Amelung et al. 2019 ^† ^, ¹⁷	Retrospective ITT analysis	BTS	222	74.0%
Arezzo et al. 2017 ¹⁸	RCT	ES	59	69% ^‡		62% ^‡
Arezzo et al. 2017 ¹⁸	RCT	BTS	56	64% ^‡		58% ^‡
Ho et al. 2017 ¹⁹	Retrospective ITT analysis	ES	40	45% ^‡	35% ^‡
Ho et al. 2017 ¹⁹	Retrospective ITT analysis	BTS	62	60% ^‡	54% ^‡
Sloothaak et al. 2014 ⁸	Follow‐up data of RCT	ES	32	78% ^‡
Sloothaak et al. 2014 ⁸	Follow‐up data of RCT	BTS	26	62% ^‡
Sabbagh et al. 2013 ²⁰	Retrospective ITT analysis	ES	39	74%	67%
Sabbagh et al. 2013 ²⁰	Retrospective ITT analysis	BTS	48	51%	30%
Tung et al. 2013 ²¹	Follow‐up data of RCT	ES	24	78% ^‡	42.8%
Tung et al. 2013 ²¹	Follow‐up data of RCT	BTS	24	76% ^‡	57.1%

^{^†}

In this study 10% of patients in the cohort presented with distant metastases.

^{^‡}

Approximate data from figures.

BTS, bridge‐to‐surgery; ES, emergency surgery; ITT, intention‐to‐treat; OS, overall survival; RCT, randomized controlled trial; RFS, relapse‐free survival.